Osavampator

pharmacological · nervous · Oral

Osavampator. Investigational positive allosteric modulator of AMPA receptors studied in humans for neuropsychiatric indications.

Investigational positive allosteric modulator of AMPA receptors studied in humans for neuropsychiatric indications.

PK: PMID:38700236 reports changes in exposure of CYP3A probe drugs; those values are not osavampator PK parameters. DOSE: PMID:36153330 studied 0.5 mg and 6 mg TAK-653 in a crossover experiment in 24 healthy volunteers; these are study doses, not an established treatment regimen. PK FULL TEXT: PMID:36153330 and PMID:38700236 cite an earlier phase 1 report for a 33.1–47.8 h half-life range. This is cited prior evidence rather than a cohort estimate measured in those papers. Their early sampling or probe-drug tables cannot establish a parent elimination constant.

Sources: PMID:38700236, PMID:36153330, PMID:34655652